Dr. van den Bos current developed technology and IP dramatically enhancing the efficacy of mesenchymal stem cells (MSCs), the productivity of cell culture media for primary cells and a novel drug target for anti-inflammatories.
Otto-Wilhelm MERTEN has a degree in biotechnology (Ph.D.) from the University of Life Sciences in Vienna (Inst. of Applied Microbiology, Prof. H. Katinger), holds an HDR at the University of Evry/Val-d’Essonne and is Visiting Professor at ITQB/UNL in Lisbon.
Magdalena Tary-Lehmann is a Co-Founding Scientist and Chief Scientific Officer for Cellular Technology Limited (CTL) and Adjunct Associate Professor of Case Western Reserve University (CASE) Department of Pathology.
Senior Consultant, Regulatory Affairs – Gene and Cell Therapies
Dr Houria Bachtarzi is a Senior Consultant, Regulatory Affairs - Gene and Cell Therapies, with a strong scientific and regulatory experience in the field of advanced biological therapies including virally vectored gene therapy
I am a classically trained chemical engineer with a deep understanding of molecular biology. My doctoral work focused on molecular virology with an emphasis on developing scalable technology for viral based gene therapy modalities.
Deputy Head, Applied Stem Cell Biology and Cell Technology
Dr. Shibashish Giri is a stem cell specialist in research and therapy. He has more than 12 years’ experience in preclinical research and clinical therapy for cell, tissue and organ regeneration in Germany.
Dr. McAllister is the Executive Director at the Amnion Foundation, a public stem cell bank that is developing technology pioneered by Dr. Anthony Atala at Mass General Hospital in Boston (www.amnionfoundation.org).
Sandra van Wetering is an expert in the development and manufacturing of cell-based products, and has in-depth knowledge the regulatory strategies and processes involved in development of such products,
Following his PhD in 1991, he worked as a managing partner in several biotechnology companies in Germany. Today he acts as Chief executive Officer Director of BioPlanta GmbH and FamiCord Deutschland GmbH.
Jean-Pierre joined Celyad in January 2016 and is responsible for strengthening the organization and key processes in manufacturing, quality, program management, clinical operations and regulatory affairs
Ajan Reginald is a Biotech entrepreneur and the co-founder and Chief Executive of Celixir plc. Celixir plc is a British cellular medicines company with drugs in late-stage clinical trials for heart failure and tendon repair and an extensive in-house product pipeline.
Dr. Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland, where he advises clients on strategy, business development, in/out-licensing, entrepreneurship and investment.
Association Of The British Pharmaceutical Industry
Paula Maria M. Alves
Paula M Alves graduated in Biochemistry at the Faculdade de Ciências da Universidade de Lisboa, and holds a PhD in Biochemical Engineering from Instituto de Tecnologia Química Biológica da Universidade Nova de Lisboa.